Woodson Equity Adds Two Veterans in Push Beyond Software Deals

Woodson Equity Partners isn't just adding headcount. The Miami-based private equity firm announced two senior hires on Tuesday that signal a strategic shift — bringing on veterans from larger platforms as it looks to scale beyond its software roots and prove it can compete for deals in healthcare and business services.

The firm brought on Randy Miller as a Principal and Matthew Holt as Vice President. Miller joins from The Riverside Company, where he spent five years as a partner focused on healthcare and business services — exactly the sectors Woodson wants to grow into. Holt comes from TPG, where he worked in the firm's growth equity group. Before that, he did stints at Apollo Global Management and Goldman Sachs.

Both hires come as Woodson manages six active portfolio companies and eyes what partners describe as an aggressive deal pipeline for the rest of 2026. The firm didn't disclose whether it's raising a new fund, but adding two experienced investors at this stage suggests capital deployment is about to accelerate.

What's notable isn't just the pedigree — it's the timing. Mid-market PE firms are facing compressed multiples, scarce financing, and increased competition from both strategics and larger funds moving downstream. Firms that can't differentiate on sector expertise or operational support are losing deals. Woodson appears to be betting that deeper benches in healthcare and services will help it win in spaces where pure-play software investors can't.

Randy Miller's track record at Riverside gives Woodson something it's lacked: credibility in healthcare services. Over five years at Riverside, Miller led or co-led investments in companies providing behavioral health, specialty pharmacy services, and healthcare IT — subsectors that have remained resilient even as broader healthcare multiples have cooled. At Riverside, he also worked on exits, meaning he's seen full deal cycles in these categories, not just entry points.

Before Riverside, Miller was a consultant at Deloitte, where he focused on healthcare strategy and M&A advisory. That background gives him both operational perspective and transaction experience — useful when evaluating roll-up platforms or carve-outs, which dominate deal flow in fragmented healthcare verticals.

He's also based in Cleveland, not Miami. That geographic footprint matters. Riverside operates out of multiple offices globally, and Miller's location gives Woodson a stronger presence in the Midwest, where healthcare services businesses often trade at lower multiples than coastal markets.

His hire suggests Woodson isn't just dabbling in healthcare — it's building the team to do multiple deals in the space. You don't bring on a principal-level hire from a top-quartile fund unless you're planning to deploy significant capital in their domain.

Matthew Holt's resume reads like a tour of the industry's upper tier. He started at Goldman Sachs in investment banking, moved to Apollo Global Management's private equity group, then landed at TPG's growth equity arm. That progression — bulge bracket bank to megafund to growth platform — is the traditional path for ambitious junior investors.

So why leave TPG for a firm that's orders of magnitude smaller?

The most likely answer: carry and deal ownership. At TPG, even senior associates and VPs often see minimal economics on individual deals. At a firm like Woodson, a VP-level hire can negotiate direct carry participation and have real influence on investment decisions. For someone early in their career, that's worth more than the brand name on the business card.

Holt's growth equity background also signals where Woodson sees opportunity. Traditional LBO math has gotten harder — debt is expensive, exit multiples are flat, and operational improvement can only drive so much value. Growth equity strategies, which rely less on leverage and more on revenue acceleration, have been outperforming in this environment. If Woodson can layer growth equity discipline onto its software and services deals, it might find better risk-adjusted returns than pure buyout plays.

Miller and Holt aren't outliers. Over the past 18 months, there's been a steady stream of mid-level investors leaving megafunds and upper-middle-market platforms for smaller firms. The reasons are structural, not anecdotal.

Woodson Equity currently manages six active portfolio companies, though the firm doesn't publicly disclose the full list. Based on prior announcements and filings, the portfolio skews heavily toward software and tech-enabled services — predictable for a firm that's built its reputation in those categories.

But six companies isn't enough to sustain a growing team. If Woodson is adding two senior investors, the implication is clear: the firm expects to close multiple new deals over the next 12-24 months. That level of activity requires either a new fund or significant dry powder from an existing vehicle.

The firm hasn't announced a fundraise, but the timing aligns with typical fund cycles. If Woodson closed its prior fund in 2022 or 2023, it's now in the deployment window where adding investment professionals makes sense. Hiring before the fund officially closes also signals confidence to LPs — it shows the firm is ready to deploy and has deal flow lined up.

What remains unclear is how Woodson will balance its legacy software focus with the new healthcare and services capabilities Miller brings. The safest bet is a barbell strategy: continue doing what's worked in vertical software, but selectively layer in healthcare services deals where Miller has conviction. That approach lets the firm expand without abandoning its core competency.

The risk is spreading too thin. Firms that try to be everything to everyone often end up with a portfolio that's hard to explain to LPs and harder to support operationally. Woodson will need to prove it can add value in healthcare at the same level it does in software — otherwise, these hires are just headcount.

Woodson is based in Miami, which has become a trendy answer to the question "where should we open an office?" in PE circles. Citadel, Blackstone, and dozens of other financial firms have expanded into South Florida over the past five years, drawn by favorable tax treatment, better weather, and the narrative that Miami is becoming the next financial hub.

But the reality is messier. Miami has capital and lifestyle. What it doesn't have yet is deal flow density. If you're investing in healthcare services or business services, most of your targets are still in the Midwest, the Mid-Atlantic, or Texas — not South Florida. That's why Miller staying in Cleveland matters. Woodson can claim Miami as its brand, but it needs people on the ground where the deals are.

To understand whether Woodson's moves are smart or reactive, it helps to look at what peer firms have done recently. Across the lower-middle and middle market, firms have been adding sector-focused investors in healthcare, government services, and industrial services — the same verticals Woodson is now targeting.

Riverside itself has continued to hire aggressively, particularly in Europe and in niche healthcare verticals. Gryphon Investors added a healthcare-focused partner in early 2025. Charlesbank Capital Partners promoted two healthcare specialists to partner last year. The pattern is consistent: firms are doubling down on healthcare because the fundamentals remain strong — aging demographics, recurring revenue models, and fragmentation that rewards roll-up strategies.

Woodson's challenge is that it's arriving late to a crowded party. Healthcare services has been a hot sector for five years. Multiples have expanded, and the easy roll-ups have already been done. The platforms that remain are either too small, too operationally complex, or already being shopped by other PE firms looking to exit.

That said, there's a counterargument: the firms that entered healthcare services in 2020-2021 paid peak multiples and are now sitting on unrealized losses or flat returns. If Woodson can buy into the sector at more rational valuations in 2026-2027, it might actually have better entry points than the early movers.

The real test isn't the hiring announcement — it's the next six to twelve months of deal activity. If Woodson closes one or two healthcare services deals in the next year, these hires look strategic. If the firm stays quiet and only does software deals, Miller becomes an expensive non-event.

A few signals to track: First, does Woodson announce a new fund? If they're adding people, they need capital to deploy. Second, do they make any add-on acquisitions in healthcare for existing portfolio companies? That would indicate they're testing the sector with lower risk before committing to a new platform. Third, do they hire more people in healthcare or services over the next six months? One principal doesn't make a sector strategy — it takes a team.

Step back, and Woodson's hires fit into a larger shift in how PE talent is moving. For the past decade, the flow was largely one-directional: ambitious investors climbed from smaller funds to larger ones, chasing brand names and bigger deal sizes. That's reversing.

Now, experienced investors are increasingly leaving large platforms for mid-market and lower-middle-market firms where they can own more of the investment process, see faster promotion timelines, and capture carry earlier in their careers. The math is simple: a 2% carry stake in a $50 million deal at a small fund can be worth more than a 0.1% stake in a $500 million deal at a megafund, especially when the smaller fund has faster exit timelines.

The other factor is workload. At firms like TPG or Apollo, junior and mid-level investors are often staffed on multiple deals simultaneously, doing diligence on businesses they'll never see again after closing. At smaller firms, they can focus on a smaller number of deals and actually help run the companies post-acquisition. For operators at heart, that's more fulfilling than being a deal machine.

Woodson is betting that it can attract and retain talent by offering those advantages. Whether it can deliver on that promise depends on execution — specifically, whether Miller and Holt actually get to lead deals, not just support them.

Healthcare services remains one of the most active sectors in middle-market PE, and for good reason. The category includes everything from home health and behavioral health to specialty pharmacy, diagnostic labs, and revenue cycle management. What ties them together: recurring revenue, defensive demand, and fragmentation.

The fragmentation piece is critical. Many healthcare services verticals are dominated by mom-and-pop operators or regional players that lack the capital or expertise to scale. PE firms can buy a platform, bolt on acquisitions, professionalize operations, and exit to a larger fund or strategic at a meaningful step-up in valuation.

Those multiples are elevated compared to five years ago, but they've come down from 2021 peaks. The question is whether they'll compress further if interest rates stay high or if demand proves durable enough to support current valuations. Miller's job will be to find the pockets where Woodson can still underwrite to attractive returns — likely in less competitive subsectors or smaller geographies.

One area to watch: value-based care platforms. These businesses, which take on financial risk for patient outcomes, have attracted massive PE investment over the past three years. But many are struggling with margin compression and regulatory scrutiny. If Woodson can buy distressed or underperforming platforms at discounts, there's alpha to be captured — but the operational risk is high.

Hiring is easy. Deploying capital into good deals is hard. Woodson's next twelve months will determine whether these additions were strategic or just headline-making.

The firm has the people now. It has the sectors identified. What it needs is proof that it can compete for quality assets in healthcare and services — and that it can create value once it owns them. In a market where multiples are high, debt is expensive, and exits are slow, operational excellence isn't optional. It's the only edge that matters.

If Miller closes a healthcare deal in the next six months that demonstrates real competitive differentiation — a proprietary angle, a complex carve-out, a distressed turnaround — Woodson will have validated the hire. If the firm stays quiet or only does software deals, the healthcare push becomes a footnote.

For now, the market will watch. And so will the LPs.